Xiao-jia Wang

List of Publications by Year
in descending order

101	1,489	394421 19	361022 35
papers	citations	h-index	g-index

104	104	104	1923
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 351-360.	10.7	188
2	Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 806-815.	10.7	154
3	Non-Invasive Biomarkers for Early Detection of Breast Cancer. Cancers, 2020, 12, 2767.	3.7	106
4	Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. OncoImmunology, 2016, 5, e1063772.	4.6	81
5	Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nature Medicine, 2021, 27, 1904-1909.	30.7	65
6	miR-181b promotes chemoresistance in breast cancer by regulating Bim expression. Oncology Reports, 2016, 35, 683-690.	2.6	56
7	Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. European Journal of Cancer, 2019, 112, 57-65.	2.8	56
8	Polymers with distinctive anticancer mechanism that kills MDR cancer cells and inhibits tumor metastasis. Biomaterials, 2019, 199, 76-87.	11.4	50
9	Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study.. Journal of Clinical Oncology, 2019, 37, 1001-1001.	1.6	48
10	PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. Nature Chemical Biology, 2022, 18, 821-830.	8.0	43
11	SOX9/FXYD3/Src Axis Is Critical for ER+ Breast Cancer Stem Cell Function. Molecular Cancer Research, 2019, 17, 238-249.	3.4	39
12	Clinicopathological Characteristics of Mucinous Breast Cancer: A Retrospective Analysis of a 10-Year Study. PLoS ONE, 2016, 11, e0155132.	2.5	35
13	Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China. Oncologist, 2017, 22, 1333-1338.	3.7	28
14	Self-Sterilizing and Regeneratable Microchip for the Precise Capture and Recovery of Viable Circulating Tumor Cells from Patients with Cancer. ACS Applied Materials & Interfaces, 2018, 10, 207-218.	8.0	27
15	Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Research and Treatment, 2020, 182, 689-697.	2.5	25
16	First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study. Clinical Cancer Research, 2022, 28, 618-628.	7.0	25
17	Expression of cluster of differentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic significance. Oncology Letters, 2015, 10, 723-729.	1.8	24
18	Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Molecular Genetics & Genomic Medicine, 2020, 8, e1079.	1.2	23

#	Article	IF	Citations
19	Construction of an mRNA-miRNA-lncRNA network prognostic for triple-negative breast cancer. Aging, 2021, 13, 1153-1175.	3.1	22
20	PET/CT Imaging for Monitoring Recurrence and Evaluating Response to Treatment in Breast Cancer. Advances in Clinical and Experimental Medicine, 2016, 25, 377-382.	1.4	20
21	TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 759154.	3.7	19
22	Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression. Oncology Reports, 2017, 37, 705-712.	2.6	18
23	Downregulation of miRâ€'200câ€'3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2. Oncology Reports, 2018, 40, 3821-3829.	2.6	18
24	Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators. JAMA Oncology, 2021, 7, e213428.	7.1	18
25	A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer. Molecular and Clinical Oncology, 2014, 2, 805-810.	1.0	16
26	Everolimusâ€containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study. Cancer Medicine, 2019, 8, 5544-5553.	2.8	16
27	Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China. Oncotarget, 2016, 7, 57301-57309.	1.8	15
28	Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). Cancer, 2020, 126, 3867-3882.	4.1	15
29	Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer. Amino Acids, 2016, 48, 487-497.	2.7	14
30	Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. Investigational New Drugs, 2020, 38, 507-514.	2.6	12
31	ADAMTS9-AS1 Constrains Breast Cancer Cell Invasion and Proliferation via Sequestering miR-301b-3p. Frontiers in Cell and Developmental Biology, 2021, 9, 719993.	3.7	12
32	Role of estrogen receptor in breast cancer cell gene expression. Molecular Medicine Reports, 2016, 13, 4046-4050.	2.4	11
33	The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients . OncoTargets and Therapy, 2020, Volume 13, 853-863.	2.0	11
34	Long non-coding RNA FOXD3 antisense RNA 1 augments anti-estrogen resistance in breast cancer cells through the microRNA-363/ trefoil factor 1/ phosphatidylinositol 3-kinase/protein kinase B axis. Bioengineered, 2021, 12, 5266-5278.	3.2	11
35	Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study. Annals of Translational Medicine, 2021, 9, 707-707.	1.7	11
36	Prognostic significance of mammary Paget’s disease in Chinese women: a 10 year, population-based, matched cohort study. OncoTargets and Therapy, 2018, Volume 11, 8319-8326.	2.0	10

#	Article	IF	Citations
37	Realâ€world efficacy and potential mechanism of resistance of icotinib in Asian advanced nonâ€small cell lung cancer with EGFR uncommon mutations: A multiâ€center study. Cancer Medicine, 2020, 9, 12-18.	2.8	10
38	The Role of Adjuvant Chemotherapy in Metaplastic Breast Carcinoma: A Competing Risk Analysis of the SEER Database. Frontiers in Oncology, 2021, 11, 572230.	2.8	10
39	Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study. Oncotarget, 2016, 7, 50643-50655.	1.8	10
40	Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer. Journal of Thoracic Disease, 2014, 6, 896-904.	1.4	10
41	Bioinformatics identification of dysregulated microRNAs in triple negative breast cancer based on microRNA expression profiling. Oncology Letters, 2018, 15, 3017-3023.	1.8	9
42	Matrine suppresses breast cancer metastasis by targeting ITGB1 and inhibiting epithelialâ€toâ€mesenchymal transition. Experimental and Therapeutic Medicine, 2020, 19, 367-374.	1.8	8
43	Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2â^' Breast Cancer Patient With High Tumor Mutational Burden. Frontiers in Oncology, 2020, 10, 588080.	2.8	7
44	Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer. Frontiers in Pharmacology, 2021, 12, 741451.	3.5	7
45	Metastases to the thyroid gland: A retrospective analysis of 21 patients. Journal of Cancer Research and Therapeutics, 2018, 14, 1515.	0.9	6
46	BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis. Journal of Breast Cancer, 2021, 24, 474.	1.9	5
47	Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nationâ€wide multicenter study. Cancer Medicine, 2021, 10, 6744-6761.	2.8	5
48	A preliminary study of pamidronic acid downregulation of angiogenic factors IGF-1/PECAM-1 expression in circulating level in bone metastatic breast cancer patients. OncoTargets and Therapy, 2016, 9, 3147.	2.0	4
49	Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 205-215.	2.3	4
50	Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China. Chinese Clinical Oncology, 2020, 9, 68-68.	1.2	4
51	An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway. Biology Open, 2020, 9, .	1.2	4
52	Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy. Oncotarget, 2017, 8, 2069-2075.	1.8	4
53	Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study.. Journal of Clinical Oncology, 2022, 40, 1031-1031.	1.6	4
54	SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. British Journal of Cancer, 2019, 120, 728-745.	6.4	3

#	Article	IF	Citations
55	Differences in the clinicopathological characteristics of pure and mixed invasive micropapillary breast carcinomas from eastern China. Annals of Translational Medicine, 2021, 9, 412-412.	1.7	3
56	Exploring the concepts and practices of advanced breast cancer treatment: a narrative review. Annals of Translational Medicine, 2021, 9, 721-721.	1.7	3
57	Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study. Annals of Translational Medicine, 2021, 9, 1334-1334.	1.7	3
58	Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).. Journal of Clinical Oncology, 2015, 33, 610-610.	1.6	3
59	Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report. Frontiers in Oncology, 2020, 10, 559057.	2.8	2
60	Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. Frontiers in Oncology, 2020, 10, 599604.	2.8	2
61	Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HRâ€‰+â€‰/HER2- advanced breast cancer. Investigational New Drugs, 2021, 39, 1549-1558.	2.6	2
62	Abstract GS1-06: A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer. Cancer Research, 2022, 82, GS1-06-GS1-06.	0.9	2
63	Remarkable Response of Toripalimab Combined with Chemotherapy in Sarcomatoid Carcinoma of Palatine Tonsil: A Case Report. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 599-604.	2.7	1
64	A multicenter, cross-sectional research of the adherence to endocrine therapy with selective estrogen receptor modulators (SERMs) in premenopausal women in China.. Journal of Clinical Oncology, 2016, 34, e12025-e12025.	1.6	1
65	Relationship of RS4646 polymorphism in CYP19A1 gene to the efficacy of hormone therapy in early breast cancer.. Journal of Clinical Oncology, 2015, 33, e11516-e11516.	1.6	1
66	Outcomes of re-treatment with first-line trastuzumab plus taxane in patients (pts) with metastatic breast cancer (mBC) who relapsed after (neo)adjuvant trastuzumab: A prospective multicenter study.. Journal of Clinical Oncology, 2016, 34, e12068-e12068.	1.6	1
67	Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review. Annals of Translational Medicine, 2022, 10, 117-117.	1.7	1
68	Abstract P2-13-40: Treatment patterns and adverse events of pyrotinib-based therapy in HER2-positive breast cancer patients in China: Results from a multicenter, real-world study. Cancer Research, 2022, 82, P2-13-40-P2-13-40.	0.9	1
69	Abstract P2-13-31: Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase 2 trial. Cancer Research, 2022, 82, P2-13-31-P2-13-31.	0.9	1
70	Abstract PD8-05: Overall survival (OS) results from the phase III PHENIX trial of HER2+ metastatic breast cancer treated with pyrotinib plus capecitabine. Cancer Research, 2022, 82, PD8-05-PD8-05.	0.9	1
71	Abstract P1-17-04: Hormone therapy (HT) brings more survival benefits than capecitabine (CAP) as maintenance therapy following the 1st-line chemotherapy in HR+/HER2-ABC/MBC: Update primary endpoint of OVERSTEP(ZJCHBC001). Cancer Research, 2022, 82, P1-17-04-P1-17-04.	0.9	1
72	Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China. Frontiers in Oncology, 2022, 12, 829693.	2.8	1

#	Article	IF	Citations
73	BRCANet: A deep hybrid network in predicting BRCA1/2 gene mutation of breast cancer with dynamic contrast-enhanced breast MRI.. Journal of Clinical Oncology, 2022, 40, e13576-e13576.	1.6	1
74	Hormone therapy (HT) or capecitabine (CAP) as maintenance therapy following the first-line chemotherapy in HR+/HER2-ABC/MBC: Secondary endpoint adverse effects (AEs) and toxicity report of OVERSTEP Trial (ZJCH15001/CBCSG 035).. Journal of Clinical Oncology, 2022, 40, 1068-1068.	1.6	1
75	Apatinib combined with chemotherapy versus single chemotherapy in HER-2 negative advanced breast cancer: A randomized, controlled, open-label phase II study.. Journal of Clinical Oncology, 2022, 40, 1072-1072.	1.6	1
76	Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage Iâ€‘II and operable stage III breast cancer. Oncology Letters, 2017, 14, 6156-6162.	1.8	0
77	Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.. Journal of Clinical Oncology, 2021, 39, e13069-e13069.	1.6	0
78	The effect of carcino-embryonic antigen and squamous cell carcinoma antigen in adjuvant diagnosis of conventional and combined small cell lung cancer.. Journal of Clinical Oncology, 2014, 32, e18551-e18551.	1.6	0
79	EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.. Journal of Clinical Oncology, 2014, 32, e18552-e18552.	1.6	0
80	Serum biomarker 3144 m/z for prognostic detection in Chinese postmenopausal breast cancer patients. Journal of Cancer Research and Therapeutics, 2015, 11, 68.	0.9	0
81	RS1008805 polymorphism in CYP19A1 gene in relation to the efficacy of hormone therapy in early breast cancer.. Journal of Clinical Oncology, 2015, 33, e11568-e11568.	1.6	0
82	Relationship of the CYP19 RS1008805 polymorphism to prognosis of stage Iâ€“II and operable stage III breast cancer.. Journal of Clinical Oncology, 2015, 33, e22088-e22088.	1.6	0
83	miRNA expression in breast cancer variance with lymph node metastasis and other clinicpathologic features.. Journal of Clinical Oncology, 2015, 33, e22084-e22084.	1.6	0
84	Prognostic impact of circulating HER2 extracellular domain (ECD) in women with metastatic breast cancer.. Journal of Clinical Oncology, 2015, 33, e22038-e22038.	1.6	0
85	Clinical characteristics and outcome of mucinous breast cancer: A retrospective analysis of 10-year study.. Journal of Clinical Oncology, 2016, 34, e13095-e13095.	1.6	0
86	A retrospective study of 21-gene recurrence score assay compared with clinicopathological markers in node-negative, hormone receptor-positive, HER2-negative breast cancer.. Journal of Clinical Oncology, 2017, 35, e12023-e12023.	1.6	0
87	Expression of androgen receptor and epidermal growth factor receptor in invasive breast cancer: A retrospective study of 1,438 patients from China.. Journal of Clinical Oncology, 2017, 35, e12587-e12587.	1.6	0
88	Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, 1003-1003.	1.6	0
89	The difference of clinicopathological characteristics between pure and mixed invasive micropapillary breast carcinoma from China.. Journal of Clinical Oncology, 2018, 36, e13107-e13107.	1.6	0
90	Assessment of PD-L1 expression in circulating tumor cells in patients with breast cancer.. Journal of Clinical Oncology, 2020, 38, e13001-e13001.	1.6	0

#	Article	IF	Citations
91	Apatinib to prolong overall survival from recurrence to death in metastatic breast cancer: A single-center experience from east China.. Journal of Clinical Oncology, 2020, 38, e13090-e13090.	1.6	0
92	Abstract OT2-27-02: A prospective phase II study on efficacy and safety of anlotinib combined with fulvestrant in patients with HR-positive and HER2-negative, secondary endocrine-resistant, locally advanced or metastatic breast cancer. Cancer Research, 2022, 82, OT2-27-02-OT2-27-02.	0.9	0
93	Abstract P2-13-10: First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: Results from a phase I study. Cancer Research, 2022, 82, P2-13-10-P2-13-10.	0.9	0
94	Abstract P1-16-02: A randomized phase II study investigating oral metronomic vinorelbine versus conventional dosage of vinorelbine in HER2-negative metastatic breast cancer previously treated with anthracycline or taxane:clinical results and biomarker analysis. Cancer Research, 2022, 82, P1-16-02-P1-16-02.	0.9	0
95	A multicenter, randomized, double-blind, phase III trial comparing denosumab biosimilar QL1206 and denosumab in patients with bone metastases from solid tumors.. Journal of Clinical Oncology, 2022, 40, 2526-2526.	1.6	0
96	Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients.. Journal of Clinical Oncology, 2022, 40, e13023-e13023.	1.6	0
97	Identified potential pathogenic variants of BARD1 in 1449 Chinese high-risk breast cancer patients.. Journal of Clinical Oncology, 2022, 40, e22525-e22525.	1.6	0
98	Development of a new HRD algorithm which was highly associated with anthracycline-containing neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2022, 40, e13575-e13575.	1.6	0
99	The population characteristic analysis in RecurIndex for clinical decision-making on adjuvant therapy for early breast cancer: Results of a real-world study.. Journal of Clinical Oncology, 2022, 40, e12514-e12514.	1.6	0
100	Platelet-to-Lymphocyte ratio (PLR) as a predictive marker in HER2 positive metastatic breast cancer patients treated with first-line trastuzumab therapy.. Journal of Clinical Oncology, 2022, 40, e13024-e13024.	1.6	0
101	The CDK4/6 inhibitor FCN-437c plus letrozole for the treatment of HR+/HER2â€“ advanced breast cancer: Updated results from a phase 1b study.. Journal of Clinical Oncology, 2022, 40, e13025-e13025.	1.6	0